The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
Next generation organofluorine containing blockbuster drugs
Abstract
The role of organo-fluorine compounds in modern health, food and energy related industries is widely-appreciated. The unique properties that fluorine imparts to organic molecules, stemming from its high electronegativity and stability when bound to carbon, finds it increasingly being used in the development of new bioactivities. Around 25 % of the current blockbuster drugs contain fluorine and this number is increasing to well above 30 % for recent FDA approvals. In this Review we highlight a selection of the most successful organo-fluorine drugs, that have achieved blockbuster status, namely, sitagliptin (diabetes), sofosbuvir (hepatitis C), emtricitabine (HIV), glecaprevir/pibrentasvir (hepatitis C), elvitegravir (HIV), dolutegravir (HIV), bictegravir (HIV), efavirenz (HIV), enzalutamide (prostate cancer), aubagio (immunomodulatory) and paliperidone palmitate (schizophrenia). For each compound we discuss their discovery, their relevant disease state and how they are made, emphasizing the source of fluorine-containing moieties, and where known, their mode of action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fluorine in medicinal chemistry
Purser, S., Moore, P. R., Swallow, S., & Gouverneur, V. (2008) · Chem. Soc. Rev. · doi:10.1039/b610213c · Cited by 7,570
Wang, J., Sánchez-Roselló, M., Aceña, J. L., del Pozo, C., Sorochinsky, A. E., Fustero, S., Soloshonok, V. A., & Liu, H. (2014) · Chemical Reviews · doi:10.1021/cr4002879 · Cited by 4,847
Self-citationZhou, Y., Wang, J., Gu, Z., Wang, S., Zhu, W., Aceña, J. L., Soloshonok, V. A., Izawa, K., & Liu, H. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00392 · Cited by 2,808
Self-citationFluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design
Meanwell, N. A. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01788 · Cited by 2,655
Contribution of Organofluorine Compounds to Pharmaceuticals
Inoue, M., Sumii, Y., & Shibata, N. (2020) · ACS Omega · doi:10.1021/acsomega.0c00830 · Cited by 1,944
Current Contributions of Organofluorine Compounds to the Agrochemical Industry
Ogawa, Y., Tokunaga, E., Kobayashi, O., Hirai, K., & Shibata, N. (2020) · iScience · doi:10.1016/j.isci.2020.101467 · Cited by 1,253
Successful fluorine-containing herbicide agrochemicals
Fujiwara, T., & O’Hagan, D. (2014) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2014.06.014 · Cited by 894
Self-citationFluorine in health care: Organofluorine containing blockbuster drugs
O’Hagan, D. (2010) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2010.03.003 · Cited by 856
Self-citationKim, D., Wang, L., Beconi, M., Eiermann, G. J., Fisher, M. H., He, H., Hickey, G. J., Kowalchick, J. E., Leiting, B., Lyons, K., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0493156 · Cited by 822
Zhu, Y., Han, J., Wang, J., Shibata, N., Sodeoka, M., Soloshonok, V. A., Coelho, J. A. S., & Toste, F. D. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00778 · Cited by 640
Self-citationRecent advances in the trifluoromethylation methodology and new CF3-containing drugs
Zhu, W., Wang, J., Wang, S., Gu, Z., Aceña, J. L., Izawa, K., Liu, H., & Soloshonok, V. A. (2014) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2014.06.026 · Cited by 493
Self-citationYoung, S. D., Britcher, S. F., Tran, L. O., Payne, L. S., Lumma, W. C., Lyle, T. A., Huff, J. R., Anderson, P. S., Olsen, D. B., & Carroll, S. S. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.12.2602 · Cited by 482
Fluorine‐Containing Drugs Approved by the FDA in 2018
Mei, H., Han, J., Fustero, S., Medio‐Simon, M., Sedgwick, D. M., Santi, C., Ruzziconi, R., & Soloshonok, V. A. (2019) · Chemistry – A European Journal · doi:10.1002/chem.201901840 · Cited by 454
Self-citationMechanism of Action for Leflunomide in Rheumatoid Arthritis
Fox, R. I., Herrmann, M. L., Frangou, C. G., Wahl, G. M., Morris, R. E., Strand, V., & Kirschbaum, B. J. (1999) · Clinical Immunology · doi:10.1006/clim.1999.4777 · Cited by 420
Origins and evolutionary consequences of ancient endogenous retroviruses
Johnson, W. E. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0189-2 · Cited by 404
Gallant, J., Lazzarin, A., Mills, A., Orkin, C., Podzamczer, D., Tebas, P., Girard, P.-M., Brar, I., Daar, E. S., Wohl, D., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32299-7 · Cited by 393
In Vitro Antiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor
Kobayashi, M., Yoshinaga, T., Seki, T., Wakasa-Morimoto, C., Brown, K. W., Ferris, R., Foster, S. A., Hazen, R. J., Miki, S., Suyama-Kagitani, A., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01209-10 · Cited by 382
Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents
Liu, S., Neidhardt, E. A., Grossman, T. H., Ocain, T., & Clardy, J. (2000) · Structure · doi:10.1016/s0969-2126(00)00077-0 · Cited by 345
Shimura, K., Kodama, E., Sakagami, Y., Matsuzaki, Y., Watanabe, W., Yamataka, K., Watanabe, Y., Ohata, Y., Doi, S., Sato, M., et al. (2008) · Journal of Virology · doi:10.1128/jvi.01534-07 · Cited by 343
Novel HIV-1 Integrase Inhibitors Derived from Quinolone Antibiotics
Sato, M., Motomura, T., Aramaki, H., Matsuda, T., Yamashita, M., Ito, Y., Kawakami, H., Matsuzaki, Y., Watanabe, W., Yamataka, K., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0600139 · Cited by 328
9α-FLUORO DERIVATIVES OF CORTISONE AND HYDROCORTISONE
Fried, J., & Sabo, E. F. (1954) · Journal of the American Chemical Society · doi:10.1021/ja01634a101 · Cited by 323
Cottrell, M. L., Hadzic, T., & Kashuba, A. D. M. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0093-2 · Cited by 298
Tsiang, M., Jones, G. S., Goldsmith, J., Mulato, A., Hansen, D., Kan, E., Tsai, L., Bam, R. A., Stepan, G., Stray, K. M., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01474-16 · Cited by 290
Jung, M. E., Ouk, S., Yoo, D., Sawyers, C. L., Chen, C., Tran, C., & Wongvipat, J. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901488g · Cited by 266
Recent Advances in Prostate Cancer Treatment and Drug Discovery
Nevedomskaya, E., Baumgart, S. J., & Haendler, B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051359 · Cited by 254
Recombining the structures of HIV integrase, RuvC and RNase H
Yang, W., & Steitz, T. A. (1995) · Structure · doi:10.1016/s0969-2126(01)00142-3 · Cited by 246
Applications of fluorine-containing amino acids for drug design
Mei, H., Han, J., Klika, K. D., Izawa, K., Sato, T., Meanwell, N. A., & Soloshonok, V. A. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111826 · Cited by 246
Self-citationFluorine-containing drugs approved by the FDA in 2019
Mei, H., Remete, A. M., Zou, Y., Moriwaki, H., Fustero, S., Kiss, L., Soloshonok, V. A., & Han, J. (2020) · Chinese Chemical Letters · doi:10.1016/j.cclet.2020.03.050 · Cited by 225
Self-citationPractical Asymmetric Synthesis of Efavirenz (DMP 266), an HIV-1 Reverse Transcriptase Inhibitor
Pierce, M. E., Parsons, R. L., Radesca, L. A., Lo, Y. S., Silverman, S., Moore, J. R., Islam, Q., Choudhury, A., Fortunak, J. M. D., Nguyen, D., et al. (1998) · The Journal of Organic Chemistry · doi:10.1021/jo981170l · Cited by 218
Structural Basis for Accommodation of Nonsteroidal Ligands in the Androgen Receptor
Bohl, C. E., Miller, D. D., Chen, J., Bell, C. E., & Dalton, J. T. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m507464200 · Cited by 210
Manna, S. K., & Aggarwal, B. B. (1999) · PubMed · Cited by 208
Bartlett, R. R., Dimitrijevic, M., Mattar, T., Zielinski, T., Germann, T., Rüde, E., Thoenes, G. H., Küchle, C. C. A., Schorlemmer, H. U., Bremer, E., et al. (1991) · Agents and Actions · doi:10.1007/bf01983301 · Cited by 189
Manna, S. K., & Aggarwal, B. B. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.4.2095 · Cited by 187
Fried, J., & Sabo, E. F. (1953) · Journal of the American Chemical Society · doi:10.1021/ja01105a527 · Cited by 181
Samtani, M. N., Vermeulen, A., & Stuyckens, K. (2009) · Clinical Pharmacokinetics · doi:10.2165/11316870-000000000-00000 · Cited by 170
First Generation Process for the Preparation of the DPP-IV Inhibitor Sitagliptin
Hansen, K. B., Balsells, J., Dreher, S., Hsiao, Y., Kubryk, M., Palucki, M., Rivera, N., Steinhuebel, D., Armstrong, J. D., Askin, D., et al. (2005) · Organic Process Research & Development · doi:10.1021/op0500786 · Cited by 167
Dolutegravir – a review of the pharmacology, efficacy, and safety in the treatment of HIV
Kandel, C., & Walmsley, S. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s84850 · Cited by 159
Human cell proteins and human immunodeficiency virus DNA integration
Turlure, F. (2004) · Frontiers in Bioscience · doi:10.2741/1472 · Cited by 159
Metabolism, Excretion, and Mass Balance of the HIV-1 Integrase Inhibitor Dolutegravir in Humans
Castellino, S., Moss, L., Wagner, D. S., Borland, J., Song, I. H., Chen, S., Lou, Y., Min, S., Goljer, I., Culp, A., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00292-13 · Cited by 157
Marinello, J., Marchand, C., Mott, B. T., Bain, A., Thomas, C. J., & Pommier, Y. G. (2008) · Biochemistry · doi:10.1021/bi800791q · Cited by 142
Vrouenraets, S. M. E., Wit, F. W. N. M., van Tongeren, J., & Lange, J. M. A. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.6.851 · Cited by 142
Tailor‐Made Amino Acids and Fluorinated Motifs as Prominent Traits in Modern Pharmaceuticals
Mei, H., Han, J., White, S., Graham, D. J., Izawa, K., Sato, T., Fustero, S., Meanwell, N. A., & Soloshonok, V. A. (2020) · Chemistry - A European Journal · doi:10.1002/chem.202000617 · Cited by 141
Self-citationTwo activities of the immunosuppressive metabolite of leflunomide, A77 1726
Xu, X., Williams, J. W., Gong, H., Finnegan, A., & Chong, A. S. (1996) · Biochemical Pharmacology · doi:10.1016/0006-2952(96)00303-6 · Cited by 138
Leflunomide: A Review of its Use in Active Rheumatoid Arthritis
Prakash, A., & Jarvis, B. (1999) · Drugs · doi:10.2165/00003495-199958060-00010 · Cited by 135
Thompson, A. S., Corley, E. G., Huntington, M. F., & Grabowski, E. J. J. (1995) · Tetrahedron Letters · doi:10.1016/0040-4039(95)01955-h · Cited by 131
Jeong, L. S., Schinazi, R. F., Beach, J. W., Kim, H. O., Nampalli, S., Shanmuganathan, K., Alves, A. J., McMillan, A., Chu, C. K., & Mathis, R. (1993) · Journal of Medicinal Chemistry · doi:10.1021/jm00054a001 · Cited by 130
Mechanosynthesis of amides in the total absence of organic solvent from reaction to product recovery
Métro, T., Bonnamour, J., Reidon, T., Sarpoulet, J., Martínez, J., & Lamaty, F. (2012) · Chemical Communications · doi:10.1039/c2cc36352f · Cited by 130
Dhillon, S. (2010) · Drugs · doi:10.2165/11203790-000000000-00000 · Cited by 127
Genetic barrier to resistance for dolutegravir.
Llibre, J. M., Pulido, F., García, F., Deltoro, M. G., Blanco, J. L., & Delgado, R. B. (2015) · PubMed · Cited by 126
Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection
Deeks, E. D. (2018) · Drugs · doi:10.1007/s40265-018-1010-7 · Cited by 125
the Montreal Primary HIV (PHI) Cohort Study Group, Oliveira, M., Ibanescu, R.-I., Anstett, K., Mésplède, T., Routy, J., Robbins, M., & BRENNER, B. G. (2018) · Retrovirology · doi:10.1186/s12977-018-0440-3 · Cited by 118
Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants
Smith, S. J., Zhao, X. Z., Burke, T. R., & Hughes, S. H. (2018) · Retrovirology · doi:10.1186/s12977-018-0420-7 · Cited by 114
Sofosbuvir: First Global Approval
Keating, G. M., & Vaidya, A. (2014) · Drugs · doi:10.1007/s40265-014-0179-7 · Cited by 112
Baumann, P., Mandl–Weber, S., Völkl, A., Adam, C., Bumeder, I., Oduncu, F. S., & Schmidmaier, R. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0664 · Cited by 112
Han, J., Sorochinsky, A. E., Ono, T., & Soloshonok, V. A. (2011) · Current Organic Synthesis · doi:10.2174/157017911794697277 · Cited by 109
Self-citationAsymmetric Autocatalysis Enables an Improved Synthesis of Efavirenz
Chinkov, N., Warm, A., & Carreira, E. M. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201006689 · Cited by 101
Elvitegravir: A New HIV Integrase Inhibitor
Shimura, K., & Kodama, E. N. (2009) · Antiviral chemistry & chemotherapy · doi:10.3851/imp1397 · Cited by 101
Han, J., Nelson, D. J., Sorochinsky, A. E., & Soloshonok, V. A. (2011) · Current Organic Synthesis · doi:10.2174/157017911794697303 · Cited by 101
Self-citationSorochinsky, A. E., Katagiri, T., Ono, T., Wzorek, A., Aceña, J. L., & Soloshonok, V. A. (2013) · Chirality · doi:10.1002/chir.22180 · Cited by 99
Self-citationMétro, T., Bonnamour, J., Reidon, T., Duprez, A., Sarpoulet, J., Martínez, J., & Lamaty, F. (2015) · Chemistry - A European Journal · doi:10.1002/chem.201501325 · Cited by 98
Kawasuji, T., Johns, B. A., Yoshida, H., Weatherhead, J. G., Akiyama, T., Taishi, T., Taoda, Y., Mikamiyama-Iwata, M., Murai, H., Kiyama, R., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301550c · Cited by 97
Sax, P. E., DeJesus, E., Crofoot, G. E., Ward, D. J., Benson, P. M., Dretler, R. H., Mills, A., Brinson, C. C., Péloquin, J., Wei, X., et al. (2017) · The Lancet HIV · doi:10.1016/s2352-3018(17)30016-4 · Cited by 95
Glecaprevir/Pibrentasvir: First Global Approval
Lamb, Y. N. (2017) · Drugs · doi:10.1007/s40265-017-0817-y · Cited by 93
7‐Step Flow Synthesis of the HIV Integrase Inhibitor Dolutegravir
Ziegler, R., Desai, B. K., Jee, J., Gupton, B. F., Roper, T. D., & Jamison, T. F. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201802256 · Cited by 92
Kawasuji, T., Fuji, M., Yoshinaga, T., Sato, A., Fujiwara, T., & Kiyama, R. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.08.043 · Cited by 90
Soloshonok, V. A., Sorochinsky, A. E., & Aceña, J. L. (2012) · Synthesis · doi:10.1055/s-0032-1316812 · Cited by 90
Self-citationHamilton, L. C., Vojnovic, I., & Warner, T. D. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702708 · Cited by 85
Clercq, E. D. (2013) · Advances in pharmacology · doi:10.1016/b978-0-12-405880-4.00009-3 · Cited by 81
Ledipasvir/Sofosbuvir: A Review of Its Use in Chronic Hepatitis C
Keating, G. M. (2015) · Drugs · doi:10.1007/s40265-015-0381-2 · Cited by 80
Review of teriflunomide and its potential in the treatment of multiple sclerosis
Kieseier, B. C. (2009) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s4474 · Cited by 79
Garvey, E. P., Johns, B. A., Gartland, M. J., Foster, S. A., Miller, W. H., Ferris, R. G., Hazen, R. J., Underwood, M., Boros, E. E., Thompson, J. B., et al. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01218-07 · Cited by 76
Sato, T., Izawa, K., Aceña, J. L., Liu, H., & Soloshonok, V. A. (2016) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201600112 · Cited by 76
Self-citationNakamura, T., Tateishi, K., Tsukagoshi, S., Hashimoto, S., Watanabe, S., Soloshonok, V. A., Aceña, J. L., & Kitagawa, O. (2012) · Tetrahedron · doi:10.1016/j.tet.2012.03.054 · Cited by 69
Self-citationMolecular mechanisms of HIV integration and therapeutic intervention
Vandegraaff, N., & Engelman, A. (2007) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399407000257 · Cited by 66
Yasumoto, M., Ueki, H., Ono, T., Katagiri, T., & Soloshonok, V. A. (2009) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2009.11.026 · Cited by 64
Self-citationCao, W. W., Kao, P. N., Chao, A. C., Gardner, P. I., Ng, J., & Morris, R. E. (1995) · PubMed · Cited by 62
Huang, O., Zhang, W., Zhi, Q., Xue, X., Liu, H., Shen, D., Geng, M., Xie, Z., & Jiang, M. (2014) · Experimental Biology and Medicine · doi:10.1177/1535370214554881 · Cited by 60
Tailor-made amino acid-derived pharmaceuticals approved by the FDA in 2019
Yin, Z., Hu, W., Zhang, W., Konno, H., Moriwaki, H., Izawa, K., Han, J., & Soloshonok, V. A. (2020) · Amino Acids · doi:10.1007/s00726-020-02887-4 · Cited by 60
Self-citationDolutegravir, a Second-Generation Integrase Inhibitor for the Treatment of HIV-1 Infection
Rathbun, R. C., Lockhart, S. M., Miller, M. M., & Liedtke, M. D. (2013) · Annals of Pharmacotherapy · doi:10.1177/1060028013513558 · Cited by 57
Wagner, R., Randolph, J. T., Patel, S. V., Nelson, L. T. J., Matulenko, M. A., Keddy, R. G., Pratt, J. K., Liu, D., Krueger, A. C., Donner, P. L., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00082 · Cited by 56
Soloshonok, V. A., Wzorek, A., & Klika, K. D. (2017) · Tetrahedron Asymmetry · doi:10.1016/j.tetasy.2017.08.020 · Cited by 54
Self-citationAbacavir/Dolutegravir/Lamivudine Single-Tablet Regimen: A Review of Its Use in HIV-1 Infection
Greig, S. L., & Deeks, E. D. (2015) · Drugs · doi:10.1007/s40265-015-0361-6 · Cited by 50
Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection.
Klibanov, O. M. (2009) · PubMed · Cited by 48
Jöckel, J., Wendt, B., & Löffler, M. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00131-2 · Cited by 46
Dolutegravir: First Global Approval
Ballantyne, A. D., & Perry, C. M. (2013) · Drugs · doi:10.1007/s40265-013-0121-4 · Cited by 44
Selected nucleos(t)ide-based prescribed drugs and their multi-target activity
Pastuch-Gawołek, G., Gillner, D., Król, E., Walczak, K., & Wandzik, I. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172747 · Cited by 43
Novel, Potent Anti-Androgens of Therapeutic Potential: Recent Advances and Promising Developments
Vasaitis, T. S., & Njar, V. C. O. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.14 · Cited by 41
Development of the Enabling Route for Glecaprevir via Ring-Closing Metathesis
Cink, R. D., LUKIN, K. A., Bishop, R. D., Zhao, G., Pelc, M. J., Towne, T. B., Gates, B. D., Ravn, M. M., Hill, D. R., Chen, D., et al. (2019) · Organic Process Research & Development · doi:10.1021/acs.oprd.9b00469 · Cited by 39
Tan, S. C., New, L. S., & Chan, E. C. Y. (2008) · Toxicology Letters · doi:10.1016/j.toxlet.2008.06.001 · Cited by 38
Elvitegravir: A Review of Its Use in Adults with HIV-1 Infection
Deeks, E. D. (2014) · Drugs · doi:10.1007/s40265-014-0206-8 · Cited by 36
Srimurugan, S., Mannam, M. R., Chakka, V., Mandapati, S. R., & Kumar, P. (2016) · Organic Process Research & Development · doi:10.1021/acs.oprd.6b00156 · Cited by 31
Weber‐Schoendorfer, C., Beck, E., Tissen‐Diabaté, T., & Schaefer, C. (2017) · Reproductive Toxicology · doi:10.1016/j.reprotox.2017.04.007 · Cited by 30
Teriflunomide: A Review of Its Use in Relapsing Multiple Sclerosis
Garnock-Jones, K. P. (2013) · CNS Drugs · doi:10.1007/s40263-013-0118-2 · Cited by 28
Qiao, G., Yang, L., Li, Z., Williams, J. W., & Zhang, J. (2015) · Clinical Immunology · doi:10.1016/j.clim.2015.01.006 · Cited by 27
Sternberg, C. N. (2019) · Future Oncology · doi:10.2217/fon-2018-0940 · Cited by 27
Andersen, J. B., Moberg, J. Y., Spelman, T. D., & Magyari, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02706 · Cited by 25
Elvitegravir for the treatment of HIV
Unger, N. R., Worley, M. V., Kisgen, J. J., Sherman, E. M., & Childs‐Kean, L. M. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1250885 · Cited by 24
Papageorgiou, C., Zurini, M. G. M., Weber, H.-P., & Borer, X. (1997) · Bioorganic Chemistry · doi:10.1006/bioo.1997.1072 · Cited by 17
An Improved Synthesis of Elvitegravir
Rádl, S., Stach, J., Píša, O., Cinibulk, J., Havlı́ček, J., Zajícová, M., & Pekárek, T. (2015) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.2477 · Cited by 14
Riva, R., Banfi, L., Castaldi, G., Ghislieri, D., Malpezzi, L., Musumeci, F., Tufaro, R., & Rasparini, M. (2011) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201001618 · Cited by 12
Bartl, R., & Frisch, B. (2009) · Springer eBooks · doi:10.1007/978-3-540-79527-8_1 · Cited by 12
Shiomi, M., Matsuki, S., Ikeda, A., Ishikawa, T., Nishino, N., Kimura, M., Kumagai, Y., & Irie, S. (2014) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.164 · Cited by 8
Cited by
Chemical Aspects of Human and Environmental Overload with Fluorine
Han, J., Kiss, L., Mei, H., Remete, A. M., Ponikvar-Svet, M., Sedgwick, D. M., Roman, R., Fustero, S., Moriwaki, H., & Soloshonok, V. A. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01263 · Cited by 537
Self-citationFluorine-containing pharmaceuticals approved by the FDA in 2020: Synthesis and biological activity
Yu, Y., Liu, A., Dhawan, G., Mei, H., Zhang, W., Izawa, K., Soloshonok, V. A., & Han, J. (2021) · Chinese Chemical Letters · doi:10.1016/j.cclet.2021.05.042 · Cited by 182
Self-citationKhan, M. F., & Murphy, C. D. (2021) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-021-11675-3 · Cited by 52
Alam, M. K., Qian, B., Davis, G. B., Donn, M., Kumar, A., Trinchi, A., Kyratzis, I. (., Kirby, J. K., Lan, M., Zhao, H., et al. (2026) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2026.120038 · Cited by 7
Metadata
- Authors
- Han, J., Remete, A. M., Dobson, L. S., Kiss, L., Izawa, K., Moriwaki, H., Soloshonok, V. A., & O’Hagan, D.
- Venue
- Journal of Fluorine Chemistry
- Publisher
- Elsevier BV
- Published
- 2020-11
- Volume
- 239
- Pages
- 109639
- ISSN
- 0022-1139 (ISSN-L)
- OpenAlex
- W3087684284
- Cited by
- 313
- References
- 102
- FWCI
- 14.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.